financetom
Business
financetom
/
Business
/
Moneycontrol Pro ties up with the Financial Times
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Moneycontrol Pro ties up with the Financial Times
Oct 19, 2020 10:24 PM

Moneycontrol Pro, India’s fastest-growing financial news subscription product, has entered an editorial-content partnership with the Financial Times. Now, Moneycontrol Pro subscribers can access insightful and in-depth content produced by world-renowned experts and journalists at the Financial Times.

Share Market Live

NSE

One of the world’s leading global news organisations, the Financial Times is recognized for its unmatched authority, integrity and accuracy. This strategic alliance will give Moneycontrol Pro users an advantage in decoding global market information and help them make better investment decisions. Pro users already have access to curated markets data, independent equity analysis, expert insights into investment styles, exclusive trading recommendations, and actionable investment ideas.

Non-users can subscribe to Moneycontrol Pro and immediately gain access to Financial Times content. Currently, we are offering a 1-year subscription plan at a special price of Rs 399 for the first year. Subscribe here.

“Moneycontrol Pro has constantly provided an edge to all our stakeholders by expanding our offerings through transformative services and collaborations,” said Manoj Nagpal, business head (B2C revenues) at Moneycontrol. “The tie-up not only reflects the same ideologies of both the platforms, but also augment our portfolio by providing Pro users with hard-hitting analyses of global policies, and financial movements.”

Angela Mackay, the Financial Times, Managing Director in Asia Pacific, said, "We are delighted to be partnering with Moneycontrol Pro to offer finance and business news and analysis to the network's audience in India. The FT’s trusted, agenda-setting journalism will enable Moneycontrol Pro to provide further value to their readers with a view to supporting the growth of their digital platform."

For those new to the story, since its launch in April 2019, Moneycontrol Pro has added over 300,000 subscribers.

Our editors parse news, trends and data to bring you daily insights and opinion for you to stay on top of the investment game. We offer deep insights into economy, business, politics and policy and more importantly, add value by writing on the intersection of these topics.

Features of Moneycontrol Pro

*On the mobile app, Pro subscribers get an ad-free experience which promises more room for data on the mobile screen with faster load times. Stock prices are also refreshed faster on the app.

*Investment ideas from our in-house equity research team and technical analysis trading ideas from a hand-picked team of experts

*Sharp commentary and opinion that will decode the news across markets, politics, policy and business.

*Exclusive access to blogs written by high net worth individuals (HNIs) and market gurus, whose life and market lessons we would all love to emulate and help us make better investment decisions.

This is only the beginning. We promise to add more features to help you stay on top of the game.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roche continues to look for obesity assets after Carmot deal
Roche continues to look for obesity assets after Carmot deal
Jul 24, 2024
FRANKFURT, July 25 (Reuters) - Roche's CEO said the Swiss company is looking into potentially acquiring further obesity drug development assets even after the $2.7 billion Carmot Therapeutics takeover, agreed in December. Speaking in a media call after the release of first-half results, CEO Thomas Schinecker also said that 25% of projects in the group's drug development pipeline had been...
AstraZeneca lifts full-year outlook on upbeat demand for therapies
AstraZeneca lifts full-year outlook on upbeat demand for therapies
Jul 24, 2024
(Reuters) -Anglo-Swedish drugmaker AstraZeneca ( AZN ) on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases. Sales in the company's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of overall sales, while other...
Unilever posts 3.9% rise in second-quarter underlying sales
Unilever posts 3.9% rise in second-quarter underlying sales
Jul 24, 2024
July 25 - Unilever ( UL ) on Thursday reported worse-than-expected underlying quarterly sales after it was unable to win back shoppers it has alienated in recent years with higher prices. ...
Australian judge dismisses lawsuit claiming Bayer weedkiller causes blood cancer
Australian judge dismisses lawsuit claiming Bayer weedkiller causes blood cancer
Jul 24, 2024
CANBERRA, July 25 (Reuters) - An Australian judge on Thursday dismissed a class action lawsuit claiming Bayer's Roundup weedkiller can cause a type of blood cancer, a boost for the company which is grappling with a slew of similar cases in the United States. Justice Michael Lee of Australia's Federal Court ruled that on the balance of probabilities, there was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved